SI-BONE Tops Q2 Estimates and Lifts 2026 Outlook as Revenue Climbs 15% and Profitability Expands

summarizeSummary

SI-BONE posted Q2 2026 revenue of $56.0 million, beating estimates, and raised its full-year guidance. Adjusted EBITDA turned positive at $2.8 million, and the company highlighted upcoming product and reimbursement tailwinds.

check_boxKey Events · Earnings and Guidance · SIBN

• Q2 Revenue Beat

  Worldwide revenue of $56.0 million grew 15.2% year-over-year, exceeding the $55.34 million consensus estimate.

• Raised 2026 Guidance

  Full-year revenue guidance was raised to $231–$233 million (from $230–$233 million), implying roughly 15–16% growth, while operating expense growth is now expected at approximately 12% (down from about 12.5%).

• Profitability Inflection

  Adjusted EBITDA improved 178% to $2.8 million, and the company generated $0.8 million in positive cash from operations.

• Upcoming Catalysts

  A 510(k) was submitted for a third breakthrough device targeting a large unmet need in spine surgery; CMS finalized a new MS-DRG family for higher inpatient payments effective October 1.

auto_awesomeAnalysis · SIBN · Industrial Applications And Services

Second-quarter revenue reached $56.0 million, surpassing the $55.34 million consensus, and full-year 2026 guidance was raised to $231–$233 million. The quarter also marked a swing to positive adjusted EBITDA of $2.8 million—a 178% improvement—and positive cash from operations. Adding to the growth story are a 510(k) submission for a third breakthrough device and a favorable CMS reimbursement ruling that takes effect October 1. Together, accelerating revenue, improving profitability, and upcoming catalysts make this a significant positive update.